Ferring Loses a Pair of Appeals to Protect Lysteda Patents

Drug Industry Daily
A A
Generic versions of Ferring Pharmaceutical’s menstrual bleeding drug Lysteda can move forward after the brandmaker lost a pair of appeals in patent infringement lawsuits seeking to block ANDAs against the product.

To View This Article:

Login

Subscribe To Drug Industry Daily